Company intelligence / Profile preview

EndoStim

St. Louis, Missouri, United Statesendostim.com ↗

Ownership: Private
Development stage: Phase 3

Overview

EndoStim has developed a first-in-class implantable neurostimulation system for drug-refractory GERD. The system delivers mild electrical stimulation to the lower esophageal sphincter to restore normal function and provide long-term reflux control. It has been successfully investigated in multiple independent studies and received FDA Breakthrough Device Designation in October 2022.

Therapeutic areas: Gastroenterology
Modalities: DeviceNeurostimulation
Industry: Implantable Medical Devices

Drug pipeline

1 asset

EndoStim System

Phase 3

Indications: Drug refractory gastroesophageal reflux disease

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on EndoStim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoStim.

Explore the full profile